299 related articles for article (PubMed ID: 37392016)
1. Sub-acute effects of psilocybin on EEG correlates of neural plasticity in major depression: Relationship to symptoms.
Skosnik PD; Sloshower J; Safi-Aghdam H; Pathania S; Syed S; Pittman B; D'Souza DC
J Psychopharmacol; 2023 Jul; 37(7):687-697. PubMed ID: 37392016
[TBL] [Abstract][Full Text] [Related]
2. Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial.
Sloshower J; Skosnik PD; Safi-Aghdam H; Pathania S; Syed S; Pittman B; D'Souza DC
J Psychopharmacol; 2023 Jul; 37(7):698-706. PubMed ID: 36938991
[TBL] [Abstract][Full Text] [Related]
3. Increased global integration in the brain after psilocybin therapy for depression.
Daws RE; Timmermann C; Giribaldi B; Sexton JD; Wall MB; Erritzoe D; Roseman L; Nutt D; Carhart-Harris R
Nat Med; 2022 Apr; 28(4):844-851. PubMed ID: 35411074
[TBL] [Abstract][Full Text] [Related]
4. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial.
Davis AK; Barrett FS; May DG; Cosimano MP; Sepeda ND; Johnson MW; Finan PH; Griffiths RR
JAMA Psychiatry; 2021 May; 78(5):481-489. PubMed ID: 33146667
[TBL] [Abstract][Full Text] [Related]
5. Psilocybin-assisted psychotherapy for depression: Emerging research on a psychedelic compound with a rich history.
Pearson C; Siegel J; Gold JA
J Neurol Sci; 2022 Mar; 434():120096. PubMed ID: 34942586
[TBL] [Abstract][Full Text] [Related]
6. Next generation antidepressants with novel mechanisms for treatment resistant depression.
Chen MH; Tu PC; Su TP
Prog Brain Res; 2023; 278():149-168. PubMed ID: 37414491
[TBL] [Abstract][Full Text] [Related]
7. Esketamine and Psilocybin-The Comparison of Two Mind-Altering Agents in Depression Treatment: Systematic Review.
Psiuk D; Nowak EM; Dycha N; Łopuszańska U; Kurzepa J; Samardakiewicz M
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232748
[TBL] [Abstract][Full Text] [Related]
8. Probing the antidepressant potential of psilocybin: integrating insight from human research and animal models towards an understanding of neural circuit mechanisms.
Meccia J; Lopez J; Bagot RC
Psychopharmacology (Berl); 2023 Jan; 240(1):27-40. PubMed ID: 36564671
[TBL] [Abstract][Full Text] [Related]
9. Psilocybin for dementia prevention? The potential role of psilocybin to alter mechanisms associated with major depression and neurodegenerative diseases.
Haniff ZR; Bocharova M; Mantingh T; Rucker JJ; Velayudhan L; Taylor DM; Young AH; Aarsland D; Vernon AC; Thuret S
Pharmacol Ther; 2024 Jun; 258():108641. PubMed ID: 38583670
[TBL] [Abstract][Full Text] [Related]
10. Towards an understanding of psychedelic-induced neuroplasticity.
Calder AE; Hasler G
Neuropsychopharmacology; 2023 Jan; 48(1):104-112. PubMed ID: 36123427
[TBL] [Abstract][Full Text] [Related]
11. Psilocybin-assisted therapy for depression: A systematic review and meta-analysis.
Haikazian S; Chen-Li DCJ; Johnson DE; Fancy F; Levinta A; Husain MI; Mansur RB; McIntyre RS; Rosenblat JD
Psychiatry Res; 2023 Nov; 329():115531. PubMed ID: 37844352
[TBL] [Abstract][Full Text] [Related]
12. [Contribution of serotonin 5-HT
Ibi D
Nihon Yakurigaku Zasshi; 2023 May; 158(3):229-232. PubMed ID: 36990794
[TBL] [Abstract][Full Text] [Related]
13. Psychedelics for treatment resistant depression: are they game changers?
Kalfas M; Taylor RH; Tsapekos D; Young AH
Expert Opin Pharmacother; 2023; 24(18):2117-2132. PubMed ID: 37947195
[TBL] [Abstract][Full Text] [Related]
14. Spectral signatures of psilocybin, lysergic acid diethylamide (LSD) and ketamine in healthy volunteers and persons with major depressive disorder and treatment-resistant depression: A systematic review.
Le GH; Wong S; Badulescu S; Au H; Di Vincenzo JD; Gill H; Phan L; Rhee TG; Ho R; Teopiz KM; Kwan ATH; Rosenblat JD; Mansur RB; McIntyre RS
J Affect Disord; 2024 Jun; 355():342-354. PubMed ID: 38570038
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up.
Gukasyan N; Davis AK; Barrett FS; Cosimano MP; Sepeda ND; Johnson MW; Griffiths RR
J Psychopharmacol; 2022 Feb; 36(2):151-158. PubMed ID: 35166158
[TBL] [Abstract][Full Text] [Related]
16. The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder.
Rosenblat JD; Husain MI; Lee Y; McIntyre RS; Mansur RB; Castle D; Offman H; Parikh SV; Frey BN; Schaffer A; Greenway KT; Garel N; Beaulieu S; Kennedy SH; Lam RW; Milev R; Ravindran AV; Tourjman V; Ameringen MV; Yatham LN; Taylor V
Can J Psychiatry; 2023 Jan; 68(1):5-21. PubMed ID: 35975555
[TBL] [Abstract][Full Text] [Related]
17. Psilocybin for the Treatment of Depression: A Promising New Pharmacotherapy Approach.
Agin-Liebes G; Davis AK
Curr Top Behav Neurosci; 2022; 56():125-140. PubMed ID: 34811715
[TBL] [Abstract][Full Text] [Related]
18. Trial of Psilocybin versus Escitalopram for Depression.
Carhart-Harris R; Giribaldi B; Watts R; Baker-Jones M; Murphy-Beiner A; Murphy R; Martell J; Blemings A; Erritzoe D; Nutt DJ
N Engl J Med; 2021 Apr; 384(15):1402-1411. PubMed ID: 33852780
[TBL] [Abstract][Full Text] [Related]
19. Sustained effects of single doses of classical psychedelics in humans.
Knudsen GM
Neuropsychopharmacology; 2023 Jan; 48(1):145-150. PubMed ID: 35729252
[TBL] [Abstract][Full Text] [Related]
20. Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants.
Galvão-Coelho NL; Marx W; Gonzalez M; Sinclair J; de Manincor M; Perkins D; Sarris J
Psychopharmacology (Berl); 2021 Feb; 238(2):341-354. PubMed ID: 33427944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
